- Home
- MRCC vs TVGN Comparison
MRCC vs TVGN Comparison
Compare MRCC & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRCC
- TVGN
- Stock Information
- Founded
- MRCC 2011
- TVGN 2020
- Country
- MRCC United States
- TVGN United States
- Employees
- MRCC N/A
- TVGN N/A
- Industry
- MRCC Investment Managers
- TVGN Blank Checks
- Sector
- MRCC Finance
- TVGN Finance
- Exchange
- MRCC Nasdaq
- TVGN Nasdaq
- Market Cap
- MRCC 176.4M
- TVGN 193.1M
- IPO Year
- MRCC 2012
- TVGN N/A
- Fundamental
- Price
- MRCC $6.40
- TVGN $1.22
- Analyst Decision
- MRCC Hold
- TVGN Strong Buy
- Analyst Count
- MRCC 1
- TVGN 1
- Target Price
- MRCC $8.00
- TVGN $10.00
- AVG Volume (30 Days)
- MRCC 84.9K
- TVGN 418.2K
- Earning Date
- MRCC 08-06-2025
- TVGN 08-13-2025
- Dividend Yield
- MRCC 15.75%
- TVGN N/A
- EPS Growth
- MRCC 3301.50
- TVGN N/A
- EPS
- MRCC 0.32
- TVGN N/A
- Revenue
- MRCC $56,983,000.00
- TVGN N/A
- Revenue This Year
- MRCC N/A
- TVGN N/A
- Revenue Next Year
- MRCC N/A
- TVGN N/A
- P/E Ratio
- MRCC $19.54
- TVGN N/A
- Revenue Growth
- MRCC N/A
- TVGN N/A
- 52 Week Low
- MRCC $6.11
- TVGN $0.26
- 52 Week High
- MRCC $8.85
- TVGN $3.09
- Technical
- Relative Strength Index (RSI)
- MRCC 48.93
- TVGN 52.80
- Support Level
- MRCC $6.32
- TVGN $1.17
- Resistance Level
- MRCC $6.50
- TVGN $1.27
- Average True Range (ATR)
- MRCC 0.16
- TVGN 0.05
- MACD
- MRCC 0.01
- TVGN 0.00
- Stochastic Oscillator
- MRCC 47.92
- TVGN 78.57
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.